BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Daewoong allowed to conduct third-stage combination therapy with diabetes drug candidate

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : November 4, 2020, 14:15 | Updated : November 4, 2020, 14:15
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Daewoong Pharmaceutical]

SEOUL -- Daewoong Pharmaceutical, a major bioengineering company in South Korea, has acquired state approval to go ahead with final clinical trials to check the efficacy and safety of enavogliflozin, a drug candidate for the treatment of diabetes when it is administered in combination with two other medications. The company aims to release the drug in South Korea by 2023.

Daewoong said it has received approval from the Ministry of Food and Drug Safety for third-stage clinical trials on triple therapy combining enavogliflozin with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors.

Metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. DPP-4 inhibitors are a class of medicine that lower high blood glucose levels. Type 2 diabetes is a common condition that causes the level of sugar (glucose) in the blood to become too high and can cause symptoms like excessive thirst.

Enavogliflozin is an SGLT2 inhibitor, also called gliflozin, that inhibits sodium-glucose transport protein 2. Gliflozins are often used in combination therapy in the treatment of type II diabetes mellitus as second or third-line agents. They may be a good option for patients who are failing with metformin monotherapy, especially if reducing weight is part of the underlying treatment.

"Enavogliflozin will be used as a treatment for patients who do not have blood sugar control even after conventional diabetes drugs were administered in combination," CEO Jeon Seng-ho said in a statement on November 4.

Type-2 diabetic patients with inadequate glycemic control by diet and exercise showed statistically significant decreases in their glycated hemoglobin levels in second-stage clinical trials, Daewoong said, adding indications for enavogliflozin would expand to a wide range of diseases.
 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Daewoong allowed to test efficacy of tapeworm treatment medicine in Philippines.
    Daewoong allowed to test efficacy of tapeworm treatment medi…
  • .Daewoong to stage clinical trials of COVID-19 treatment using stem cells .
    Daewoong to stage clinical trials of COVID-19 treatment usin…
  • .Daewoong agrees to sell therapeutic botox product through U.S. partner.
    Daewoong agrees to sell therapeutic botox product through U.…
  • .Daewoong seeks Philippine approval to test tapeworm treatment medicine .
    Daewoong seeks Philippine approval to test tapeworm treatmen…

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Hanwha Systems works with antenna manufacturer to develop on-the-move satellite communication termin…
  • Naver and Korean Air join hands to interlink services
  • Hyosung Heavy localizes medium-voltage direct current transmission system
  • Samsung Electronics develops new technology to improve 5G network performance
  • S. Korea to share know-how of biodegradable fishing net production with Kuwait
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view